Loading
Full Opioid Agonist·Addiction Medicine
TGA/PBS — Opioid agonist treatment for opioid dependence under supervised program arrangements; methadone products also have analgesia indications depending on formulation/product
Max Dose
Titrated
Half-life
15-60 h
QTc Risk
DOSE-DEP
Overdose Risk
CRITICAL INIT.
Overview
Long-acting full mu-opioid receptor agonist used in opioid agonist treatment and selected pain settings. Its long, variable half-life makes supervised initiation and slow titration essential.
Maximum Dose
No simple fixed maximum for OAT; titrate under specialist/program protocol. MATOD guidance describes maintenance generally 60-100 mg, with induction increases kept slow.
Clinical Focus
Methadone accumulates because respiratory-depressant effects last longer than analgesic effects and the half-life is highly variable. Early dose increases must be conservative, with sedation/respiratory checks before escalation.
Bottom Line
Methadone is effective but high-risk: initiation/titration, QTc risk, CNS depressant interactions, renal/hepatic impairment, pregnancy/neonatal issues, and program access rules need active management.
Brand Names
Biodone Forte, Physeptone
Oral Routes
Oral liquid syrup (5 mg/mL). Tablets (10 mg).
Prescribing & PBS
Methadone access depends on indication, formulation, and local OAT program rules. PBS item 13334T covers methadone hydrochloride oral liquid; confirm jurisdictional authority, supervised dosing, and dispensing requirements.
Primary
TGA/PBS — Opioid agonist treatment for opioid dependence under supervised program arrangements; methadone products also have analgesia indications depending on formulation/product.
Clinical Place
Highly effective for retaining severe addicts in treatment due to the lack of withdrawal/craving, but carries far higher toxicity risks than Buprenorphine.